-
Br J Cancer: CDX2 regulates the expression of Snail and the stability β-catenin to inhibit the invasion and metastasis of colorectal cancer
Time of Update: 2020-12-16
Previous studies have shown that CDX2 is involved in the development of various cancers and plays a vital role in the invasion and metastasis of cancer, but the role of CDX2 in the CRC endosthast-interstital transformation (EMT) process is still unknown.
-
Eur J Cancer: ERCC3, a new risk gene for ovarian cancer?
Time of Update: 2020-12-16
in patients of German Jewish descent, the relapsed hybrid short-cut mutation of the ERCC3 gene increases the risk of breast cancer.
researchers analyzed multiple genes, including ERCC3, from 1,311 patients, and compared 453 Spanish cancer-free individuals with 51,343 non-Finnish, non-cancer European individuals.
-
Pit Girl's cancer! Fuyang 33-year-old second-born bao mother pregnant "cancer" climbed into the brain, did not expect to be the scourge of the fetus
Time of Update: 2020-12-16
November 3, Director Qian Jianhua received a paraplegic and aphatic Sasha, she immediately carried out a detailed assessment of the young mother's condition, very unfortunate, Sasha "trick" disease is highly malignant velvet cancer (phase IV), accompanied by multiple metastasis of the lungs, kidneys and brain, belonging to the very high-risk pregnancy nourishing cell tumors.
-
The innovative targeted drug RET inhibitor Pralsetinib Extended Adaptation has been approved by the FDA to treat thyroid cancer
Time of Update: 2020-12-15
At present, China's State Drug Administration has accepted Platini as a national 1.1 new drug market application on September 4 this year, and included it in the priority review, for the treatment of platinum-containing chemotherapy RET fusion positive non-small cell lung cancer patients.
-
STM: To improve the effectiveness of solid tumor treatment, Zhang Can team of China University of Pharmacy developed T-cell surface anchoring technology
Time of Update: 2020-12-15
team proposed a new strategy for combining the lipid metabolic regulator Avasimibe with step-by-step T cells for solid tumor therapy.
use T-cell surface anchoring engineering technology to achieve metabolic regulation and cross-T-cell therapy in collaboration with the treatment of solid tumors.
-
China's first cancer early screening registration certificate was approved, early screening market ushered in a new change
Time of Update: 2020-12-15
At the " press conference, Dr. Chen Yiyou, Chief Scientist of Nohui Health, on behalf of the company, donated RMB 1 million to the Zhengshu Oncology Development Fund of Zhejiang University Education Foundation Medical College, in honor of professor Zheng Shu, the 90-year-old "first person in China for early screening of colorectal cancer".
-
Han Baohui: Year-end inventory of progress in targeted treatment of lung cancer in 2020
Time of Update: 2020-12-15
Despite the cancellation of major offline meetings in lung cancer such as ASCO, ESMO and WCLC in 2020 due to the outbreak of neo-crown pneumonia, there are still a number of major studies this year th
-
ARCH PATHOL LAB MED: Blood lymphomas rarely manifest as undifferentiated polysomas of soft tissue
Time of Update: 2020-12-15
purpose of this study is to investigate the misdiagnosis of polyscopic hemolymphomas such as mesolytic large cell lymphoma, diffuse large B-cell lymphoma, tissue cell sarcoma, myelin sarcoma, and fable degenerative cell sarcoma.
-
Nat Commun: "Enhanced subcapajaja" event determines the structure of ecDNA MYCN amplification in neuroblastoma
Time of Update: 2020-12-15
has identified five specific enhancers in neuroblastoma cells that express MYCN, and previous studies have shown that amplification of the MYCN gene is a driving force behind one in six neuroblastomas.
-
Br J Cancer: The effect of RAS mutation on the overall survival of patients with early and late colorectal cancer liver metastasis
Time of Update: 2020-12-15
study showed that the younger the age of onset of CRC, the greater the negative impact on the overall survival of RAS mutations in LOCRC, EOCRC and ≤40 years of age (risk ratio (HR) of 1.64, 2.03 and 2.97, respectively).
-
Cell Death Differ: DYRK2 activates HSF1 to enhance resistance to protein toxic stress and promote the development of triple negative breast cancer
Time of Update: 2020-12-15
importantly, in tumors in TNBC patients, the expression level of DYRK2 is positively associated with active HSF1 and is related to the patient's poor prognostics, which also indicates that DYRK2 can promote the development of TNBC.
-
Nat Commun: SOX2/GLI1-ST3GAL1-AXL pathline promotes melanoma metastasis
Time of Update: 2020-12-15
further studies have shown that ST3GAL1 can drive the metastasis of melanoma.
all, the results show that the ST3GAL1-AXL pathline is the key to driving melanoma metastasis, targeting that path path or potential treatment strategy for metastasis melanoma.
-
Cell: New target Serpin B9 directly mediats tumor damage and cancer immunotherapy
Time of Update: 2020-12-15
source: Cell However, the researchers did not observe differences in Treg, TAM (M1 and M2) and MDSC levels between WT and tumor cells that knocked out Sb9, suggesting that the expression of tumor Sb9 had little effect on the proportion of immunosuppressive cell populations in TME.
-
Nat Commun:EZH2-mediated PP2A infraste-mediated resistance to HER2 targeted therapy for breast cancer
Time of Update: 2020-12-15
Genetic knock-off or inhibition of EZH2 by EZH2 inhibitors restores the expression of PPP2R2B, removes residual phosphorylation of p70S6K and 4EBP1, and makes HER2 plus breast cancer cells resensitive to HER2 targeted therapy.
-
STM: Three Strategies to Achieve a New Generation of Lysolyvirus Development (Jia for National Review)
Time of Update: 2020-12-15
engineered adenovirus Ad5-3M is introduced with mutations to reduce inflammation after systemic drugation and to avoid interaction with blood factors and immune cells (video source: Dmitry Shayakhmetov) Human adenovirus (HAdv) is very effective in infecting and killing various types of cancer cells.
-
2020 CCO |。 Prof. Zhang Qingxuan: Advances in the treatment of external T-cell lymphoma
Time of Update: 2020-12-15
A forward-looking, observational final analysis of the study (ODICE study) in France assessed the treatment of BV in patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), where the median cycle number of different PTCL subtypes for BV therapy was 4-7 lines, ORR was 37% to 71%, and median PFS was 3.6 to 8.4 months.
-
NEJM: Mother cell plasma cell-like degeneroma - case reported
Time of Update: 2020-12-15
patients received a 1-week course of treatment for dexamisong, and skin lesions were significantly reduced (figure B).
after 6 months of cure, the disease returned and the patient did not respond to further treatment.
-
Adequate preoperative assessment is an early for successful surgery with co-operative abdominal aortic aneurysm
Time of Update: 2020-12-15
in clinical settings, clinicians routinely recommend coronary CTA or DSA testing in patients with abdominal aortic aneurysms; treatment of abdominal aortic aneurysms with combined coronary disease is generally an individualized selection strategy based on the patient's condition.
-
JAMA: HFE p.C282Y men with pure co-children had a significantly increased risk of liver cancer
Time of Update: 2020-12-15
study found that male HFE p.C282Y pure co-carriers had a significantly increased risk of developing liver malignancies and death, compared to men, female pure-son carriers had a lower risk.
-
Scientists have discovered new cancer immunotherapy based on nanobiology
Time of Update: 2020-12-15
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
